alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (NCT03692429)

🧪 Interventions in This Study

• CYAD-101 (DRUG)
• FOLFOX (DRUG)
• FOLFIRI (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Histologically proven metastatic adenocarcinoma of the colon or rectum.
2. Confirmed metastatic unresectable adenocarcinoma of the colon or the rectum.
3. Recurrent/progressing disease after at least one line of systemic therapy for metastatic disease.
4. Unequivocal and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
5. FOLFOX segment: Neurotoxicity less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 from previous chemotherapy.
6. FOLFIRI segment: Documented progressive disease (PD) under FOLFIRI treatment, with or without targeted therapy, given within 3 months prior to study registration. Anti-cancer therapy post FOLFIRI-documented PD prior to study registration is authorized if discontinued at least 7 days before the planned study registration. Radiotherapy is not authorized.
7. The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
8. The patient must have adequate bone marrow reserve, hepatic, renal, pulmonary and cardiac functions.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (4 Sites)

• Moffit Cancer Center — Tampa, Florida
• Institut Jules Bordet — Brussels,
• UZ Antwerpen — Edegem,
• UZ Leuven — Leuven,

📞 Contact the Study Coordinator

Phone: (321) 039-4100

Email: clinicaltrials@celyad.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Unresectable Metastatic Colorectal Cancer

• Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer — Jacksonville, Florida
• First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer — Baltimore, Maryland
• Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab — Phoenix, Arizona

Explore by condition: All Unresectable Metastatic Colorectal Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.